New EPO Products Set To Boost Future Revenue For 3SBio
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30
You may also be interested in...
Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery
BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next
Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery
BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next
Malaysia Releases Regulatory Guidance On Biosimilars, But Local Manufacturers Not Ready To Produce - Analyst
PERTH, Australia - Malaysia's Ministry of Health released guidelines for registering biosimilars in Malaysia last month - making Malaysia likely the first Southeast Asian nation to set a regulatory framework for the new breed of follow-on biologics